Oral Care Ingredient Dosage Form Flexibility Urged By P&G, Pfizer
This article was originally published in The Rose Sheet
Executive Summary
Category I active ingredient dosage forms other than those reviewed by the Dental Plaque Subcommittee should be allowed in the antiplaque/antigingivitis final monograph, according to Pfizer
You may also be interested in...
Oral Care Heavyweights Disagree On Plaque Claim Support, Stannous Fluoride
Procter & Gamble and Pfizer take opposing views on the way therapeutic standalone antiplaque claims should be regulated in comments submitted to FDA Feb. 20
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program